IP Library Granted Patent US 7,632,944
Granted Patent B2
US 7,632,944 · App. 11/626,397 · Granted Dec 15, 2009

Quinolone carboxylic acids, derivatives thereof, and methods of making and using same

Assignee: Bausch & Lomb Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,632,944
App. No.
11/626,397
Filed
Jan 24, 2007
Granted
Dec 15, 2009
Kind
B2
Art Unit
1624
USPC
540/484
Abstract

A process of preparing a quinolone carboxylic acid or its derivatives having Formula I, Ia, or IV, as shown herein, comprises using a starting quinolone that already has one or more desired substituents at one or more particular positions on the quinolone ring and preserving the orientation of such substituents throughout the synthesis. The present process comprises fewer steps than prior-art processes. The present process also can include a simple separation of a desired enantiomer of the quinolone carboxylic acid or its derivatives from the enantiomeric mixture. Pharmaceutical compositions comprising fluoroquinolones prepared by the present process can be used effectively against a variety of microbial pathogens.

Claims (17)

1. A process of preparing a fluoroquinolone enantiomer having Formula IV or salts thereof, the method comprising:

(a) contacting a first compound having Formula II with a third compound having Formula V to produce a fourth compound having Formula VI, wherein the fluoroquinolone having Formula IV, the first compound, the third compound, and the fourth compound are represented by

 wherein R 1 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, and groups that can be hydrolyzed in living bodies; R 3 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted lower alkoxy groups, substituted lower alkoxy groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, unsubstituted C 5 -C 24 aryloxy groups, substituted C 5 -C 24 aryloxy groups, unsubstituted C 5 -C 24 heteroaryloxy groups, substituted C 5 -C 24 heteroaryloxy groups, and groups that can be hydrolyzed in living bodies; X is selected from the group consisting of halogen atoms; Y is CH 2 ; Z is selected from the group consisting of oxygen and two hydrogen atoms; and R 5 comprises a protected amino group having a formula or —NR 6 , wherein R 6 comprises a protecting group that is capable of leaving the protected amino group —NR 6 ; and

(b) contacting the fourth compound with a sufficient amount of a catalyst and at a condition sufficient to effect a cleavage of the protecting group R 6 from the —NR 6 group, to produce a fluoroquinolone having Formula IV;

wherein the orientation of R 2 is preserved throughout the process.

2. The process of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 6 -C 14 substituted and unsubstituted aryl groups, C 6 -C 14 substituted and unsubstituted heteroaryl groups, and groups that can be hydrolyzed in living bodies; R 3 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 1 -C 5 substituted and unsubstituted alkoxy groups, C 5 -C 14 substituted and unsubstituted aryl groups, C 5 -C 14 substituted and unsubstituted heteroaryl groups, and C 5 -C 14 substituted and unsubstituted aryloxy groups; R 6 is selected from the group consisting of nitrophenylalkylidene, t-Boc, and Fmoc; and X is selected from the group consisting of Cl, F, and Br.

3. The process of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups and groups that can be hydrolyzed in living bodies; R 3 is selected from the group consisting of C 3 -C 10 cycloalkyl groups; R 6 comprises a nitrophenylalkylidene group; X is selected from the group consisting of Cl and F; Y comprises CH 2 ; and Z comprises two hydrogen atoms.

4. The process of claim 1 , wherein the catalyst is selected from the group consisting of acids and bases.

5. The process of claim 3 , wherein the step of contacting is carried out at a temperature in a range from about room temperature to about 100° C.

6. The process of claim 3 , wherein the catalyst is hydrochloric acid.

7. The process of claim 1 , wherein the process further comprises recovering the enantiomer is carried out by recrystallization.

8. A process for preparing a fluoroquinolone carboxylic acid enantiomer having Formula Ia or salts thereof, the process comprising:

(a) contacting a compound having Formula IIa with a compound having Formula VIIa at a temperature in the range from about room temperature to about 100° C. for a time from about 10 minutes to about 7 days, to produce a compound having Formula VIa, wherein the fluoroquinolone having Formula Ia and the compounds having Formulae IIa, VIa, and VIIa are represent by

(b) contacting the compound having Formula VIa with an amount of HCl equal to about 0.1 to about 5 moles per mole of the compound having Formula VIIa at a temperature in the range from about room temperature to about 100° C., in a presence of methanol to produce the fluoroquinolone carboxylic acid having Formula Ia; and

(c) recovering the fluoroquinolone carboxylic acid enantiomer having Formula Ia;

wherein the orientation of the amino group is presented throughout the process.

9. The process of claim 8 , wherein the step of recovering the fluoroquinolone carboxylic acid enantiomer is carried out by recrystallization.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Apr 19, 2010
From: WP PRISM, INC.; BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B & L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE AG, AS ADMINISTRATIVE AGENT
Reel/Frame 024244/0812 →
SECURITY AGREEMENT Recorded Nov 16, 2007
From: BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; IOLAB CORPORATION; RHC HOLDINGS, INC.; WP PRISM, INC.
To: CREDIT SUISSE
Reel/Frame 020122/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2007
From: HARMS, ARTHUR E.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 018795/0270 →
Continuity (1)
Related Publication 20080176834A1 · Jul 24, 2008